Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

(2018) Koji Haratani et al.   JAMA Oncology

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Yoon-Koo Kang et al.   LANCET

Adverse kidney effects of epidermal growth factor receptor inhibitors

(2017) Hassan Izzedine et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor

(2017) Julia Escandon et al.   Journal for ImmunoTherapy of Cancer

Acute interstitial nephritis related to immune checkpoint inhibitors

(2016) Julie Belliere et al.   BRITISH JOURNAL OF CANCER

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY